- Dosing patients in MAGE-A10 lung cancer study at one billion target cell dose -
- Updated MRCLS response data will be presented in an oral presentation at
- Guidance confirmed, funded through to early 2020 -
- Conference call to be held today at 8:00 a.m. EDT (
“2018 is off to an outstanding start, and the remainder of the year promises to be even more exciting for Adaptimmune as we look forward to response data from our wholly owned assets in a variety of solid tumors,” commented
Adaptimmune continues to make good progress across all trial cohorts. Clinical data highlights include:
- Initial safety data (https://bit.ly/2HAuhTS) with Adaptimmune’s wholly owned SPEAR T-cell therapy targeting MAGE-A10 reported in January. These data will be presented and updated in a poster at the upcoming
American Society of Clinical Oncology( ASCO) annual meeting in June.
- Dosing at the target dose of one billion transduced SPEAR T-cells in the MAGE-A10 triple tumor study reported in January (https://bit.ly/2HAuhTS).
- Dosing at the target dose of one billion transduced SPEAR T-cells after recent recommendation from the scientific review committee (SRC) to dose escalate in the MAGE-A10 non-small cell lung cancer (NSCLC) study.
- Responses in a second solid tumor, myxoid round/cell liposarcoma (MRCLS), with NY-ESO reported in March (https://bit.ly/2HAluxz). These data will be presented and updated at an oral presentation during
Initial safety data from the MAGE-A4 “basket study” (required to support dose escalation to one billion cells) is on track for the second quarter of 2018. MAGE-A4 response data and initial AFP safety data are anticipated throughout the second half of this year.
In another important step towards its ambition to become a fully integrated cell therapy company, Adaptimmune has now received regulatory approval to produce SPEAR T-cells for all of its wholly owned programs (MAGE‑A10, MAGE-A4, and AFP) at its Philadelphia Navy Yard facility. The Company is routinely manufacturing SPEAR T-cells at the Navy Yard, and achieving cell volumes in the range of the therapeutic doses seen with NY‑ESO in synovial sarcoma.
In addition, Adaptimmune announced in
Wholly owned programs
Continued momentum towards safety and response readouts from SPEAR T-cells targeting MAGE-A10 and MAGE-A4 in multiple solid tumors throughout the second half of 2018, and initial safety data from AFP in hepatocellular carcinoma anticipated in late 2018
- Dosing at one billion target cell dose in both pilot studies (NSCLC and “triple tumor”)
- To date, no evidence of off-target toxicity in MAGE-A10 pilot studies in patients who received 100 million cells
- Response data anticipated in the second half of 2018
- Preclinical data presented at the
American Association for Cancer Research(AACR) annual meeting in April 2018support the potential specificity and potency of Adaptimmune’s MAGE‑A10 SPEAR T-cells (https://bit.ly/2HulQJG)
- Basket study: Dosing continues and on schedule to report initial safety data in Q2 2018
- Response data are anticipated throughout the second half of this year
- Preclinical safety data presented at AACR identified no major safety concerns for MAGE-A4 SPEAR T‑cell, and analyses of NSCLC tumor samples support the validity of MAGE‑A4 as a target in this indication (https://bit.ly/2HulQJG)
- Hepatocellular carcinoma: Study open and enrolling with initial safety data anticipated in late 2018
- Next generation SPEAR T-cells
- Adaptimmune’s US patent US15/713464 covering a “next generation” approach to making our T‑cells resistant to the immunosuppressive environment of solid tumors, has been granted. This approach is likely to be used in some of the Company’s future clinical trials.
NY-ESO program (partnered with GSK)
Compelling clinical data supports the potential of Adaptimmune’s TCR T-cell therapies to treat solid tumors
- MRCLS: Update will be presented in an oral presentation at
- GSK option exercise and transition: The transition of the NY-ESO program to GSK is ongoing.
Adaptimmune is building a fully integrated cell therapy company
- Received regulatory approval to produce SPEAR T-cells for all of its wholly owned programs (MAGE-A10, MAGE-A4, and AFP) at its Philadelphia Navy Yard facility.
- Routinely manufacturing SPEAR T-cells at the Navy Yard, and achieving cell volumes in the range of the therapeutic doses seen with NY ESO in synovial sarcoma.
- Announced in
January 2018(https://bit.ly/2D8A52t ) that it had executed an agreement with CGT Catapult for its own dedicated manufacturing space to secure vector supply for the medium term for ongoing studies with all three wholly owned SPEAR T-cell therapies.
- The Catapult space is now officially open.
- Had a US patent granted (US9932597), covering a “WPRE-free" vector system, that will further optimize the vector system used for manufacture of its SPEAR T-cells.
Other corporate news
Adaptimmune is in a strong financial position to deliver success with SPEAR T-cell therapies
- Funded through to early 2020 with cash and cash equivalents of
$53.4 million and total liquidity1 of $161.8 million
- Announced in
April 2018(https://bit.ly/2v7v3D3 ) that John Furey, Chief Operating Officer at Spark Therapeutics, was appointed as an independent Non‑Executive Director to Adaptimmune’s Board of Directors (effective July 5, 2018)
Financial Results for the three-month period ended
- Cash / liquidity position: As of
March 31, 2018, Adaptimmune had cash and cash equivalents of $53.4 million and Total Liquidity1 of $161.8 millionthat will fund the Company through early 2020 based on management’s estimates.
- Revenue: With effect from
January 1, 2018, the Company has adopted a new accounting standard2. Under this new accounting standard, revenue represents the upfront payment and milestones under the GSK Collaboration and License Agreement, which are recognized based on the percentage completion of the NY-ESO and PRAME development programs. Revenue for the three months ended March 31, 2018was $8.2 million. Revenue for the three months ended March 31, 2018under the previous guidance would have been $9.0 million, compared to $2.9 millionfor the same period of 2017. This increase in revenue, compared to the same period in 2017, is primarily due to a reduction in the period over which the Company is recognizing revenue following GSK’s exercise of its option over the NY-ESO program in September 2017and additional development milestones achieved.
- Research and development (“R&D”) expenses: R&D expenses for the three months ended March 31, 2018 were
$25.7 million, compared to $18.6 millionfor the same period of 2017. The increase was primarily due to increased costs associated with clinical trials, manufacturing for clinical trials, and increased personnel costs.
- General and administrative (“G&A”) expenses: G&A expenses for the three months ended March 31, 2018 were
$11.2 million, compared to $6.5 millionfor the same period of 2017. The increase was primarily due to increased personnel costs consistent with the Company’s planned growth, an increase in costs associated with developing its IT infrastructure and an increase in other corporate costs.
- Other income, net: Other income for the three months ended
March 31, 2018was $7.1 million, compared to $0.4 millionfor the same period of 2017. Other income primarily comprises unrealized foreign exchange gains, which fluctuate depending on exchange rate movements and the amount of foreign currency assets and liabilities.
- Net loss: Net loss attributable to holders of the Company’s ordinary shares for the three months ended
March 31, 2018was $21.1 million( $(0.04)per ordinary share) compared to $21.8 million( $(0.05)per ordinary share) in the same period of 2017.
The Company believes that its existing cash, cash equivalents, marketable securities and income from GSK upon transition of the NY-ESO program will fund the Company’s current operating plan through to early 2020.
1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
2 ASC 606, Revenue from Contracts with Customers.
Conference call information
The Company will host a live teleconference and webcast to provide additional details at
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (
Total liquidity (a non-GAAP financial measure)
Total Liquidity is the total of cash and cash equivalents, and marketable securities. Each of these components appears in the Consolidated Balance Sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the Consolidated Financial Statements, which reconciles to Total Liquidity as follows:
|Cash and cash equivalents||$||53,375||$||84,043|
The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its management of overall liquidity, financial flexibility, capital structure and leverage.
Condensed Consolidated Statement of Operations
(unaudited, in thousands, except per share data)
|Three months ended
|Research and development||(25,732||)||(18,615||)|
|General and administrative||(11,204||)||(6,463||)|
|Total operating expenses||(36,936||)||(25,078||)|
|Other income, net||7,130||430|
|Loss before income taxes||(20,951||)||(21,551||)|
|Net loss attributable to ordinary shareholders||$||(21,078||)||$||(21,782||)|
|Net loss per ordinary share - Basic and diluted||$||(0.04||)||$||(0.05||)|
|Weighted average shares outstanding - Basic and diluted||562,381,995||428,961,818|
Condensed Consolidated Balance Sheets
(unaudited, in thousands)
|Cash and cash equivalents||$||53,375||$||84,043|
|Marketable securities - available-for-sale debt securities||108,459||124,218|
|Accounts receivable, net of allowance for doubtful accounts of $- and $-||5,052||206|
|Other current assets and prepaid expenses (including current portion of clinical materials)||28,777||21,716|
|Total current assets||195,663||230,183|
|Property, plant and equipment, net||41,235||40,679|
|Liabilities and stockholders’ equity|
|Accrued expenses and other accrued liabilities||19,650||27,201|
|Total current liabilities||51,922||74,314|
|Other liabilities, non-current||3,884||3,849|
|Common stock - Ordinary shares par value £0.001, 701,103,126 authorized and 564,859,960 issued and outstanding (2017: 701,103,126 authorized and 562,119,334 issued and outstanding)||858||854|
|Additional paid in capital||461,603||455,401|
|Accumulated other comprehensive loss||(27,136||)||(21,641||)|
|Total stockholders’ equity||191,262||202,984|
|Total liabilities and stockholders’ equity||$||247,068||$||281,147|
Condensed Consolidated Cash Flow Statement
(unaudited, in thousands)
| Three months ended
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Share-based compensation expense||4,672||2,686|
|Realized loss on available-for-sale debt securities||1,163||-|
|Unrealized foreign exchange gains||(7,862||)||(52||)|
|Changes in operating assets and liabilities:|
|Increase in receivables and other operating assets||(10,179||)||(1,813||)|
|Increase in non-current operating assets||(123||)||(17||)|
|Decrease in payables and deferred revenue||(15,879||)||(8,507||)|
|Net cash used in operating activities||(47,279||)||(28,439||)|
|Cash flows from investing activities|
|Acquisition of property, plant and equipment||(1,904||)||(12,249||)|
|Acquisition of intangibles||(10||)||(242||)|
|Maturity of short-term deposits||-||7,854|
|Investment in short-term deposits||-||(18,000||)|
|Maturity or redemption of marketable securities||28,043||-|
|Investment in marketable securities||(12,490||)||-|
|Net cash provided by (used in) investing activities||13,639||(22,637||)|
|Cash flows from financing activities|
|Proceeds from issuance of common stock, net of issuance costs $4,774||-||61,397|
|Proceeds from exercise of stock options||1,534||-|
|Net cash provided by financing activities||1,534||61,397|
|Effect of currency exchange rate changes on cash, cash equivalents and restricted cash||1,545||1,491|
|Net (decrease) increase in cash, cash equivalents and restricted cash||(30,561||)||11,812|
|Cash, cash equivalents and restricted cash at start of period||88,296||162,796|
|Cash, cash equivalents and restricted cash at end of period||$||57,735||$||174,608|
Sébastien Desprez – VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
T: +1 215 825 9310
M: +1 215 460 8920
Source: Adaptimmune Therapeutics plc